Guardant Health, Inc. (NASDAQ: GH) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
Guardant Health, Inc. (NASDAQ: GH) had its price target lowered by analysts at Barclays PLC from $60.00 to $55.00. They now have an "overweight" rating on the stock.
Guardant Health, Inc. (NASDAQ: GH) is now covered by analysts at Mizuho. They set an "outperform" rating and a $55.00 price target on the stock.
Alpenglow Biosciences Expands Advisory Board with Two Esteemed Industry Leaders [Yahoo! Finance]